Baxter creates Vitesse as early R&D engine

As Baxter gets ready to transition out its pharma portfolio into a freestanding company, the pharma's venture arm is teaming up with the Mayo Clinic and Velocity Pharmaceutical Development to create a new early-stage biotech dubbed Vitesse Biologics.

The biotech will focus on hematology, immunology and oncology with each of the contributing entities providing their expertise to help...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

More from Scrip